Page 124 - Educacional Ponenecias Congreso SEHH-STH 2020

group of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018
Mar;103(3):438-46.
11. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-
blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med.
2012;366(9):799-807.
12. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et
al. JAK inhibition with ruxolitinib versus best available therapy for myelofibro-
sis. N Engl J Med. 2012;366(9):787-98.
13. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA,
et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-45.
14. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790-7.
15. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinua- tion. Blood. 2017 Aug 31;130(9):1125-31.
16. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2
inhibitor ruxolitinib: survival advantage in comparison to matched historical
controls. Blood. 2012;120(6):1202-9.
17. Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, et al. Life
after ruxolitinib: Reasons for discontinuation, impact of disease phase, and
outcomes in 218 patients with myelofibrosis. Cancer. 2020;126(6):1243-52. 18. L u s s a n a F, C a t t a n e o M , R a m b a l d i A , S q u i z z a t o A . R u x o l i t i n i b - a s s o c i a t e d i n f e c t i o n s :
a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339-47.
19. Polverelli N, Breccia M, Benevolo G, Martino B,Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A
multicenter study of 507 patients. Am J Hematol. 2017;92(1):37-41.
20. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary My-
elofibrosis: a Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643-51.
21. Harrison CN,Schaap N,Vannucchi AM,Kiladjian JJ,Jourdan E,Silver RT,et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib
failure. Am J Hematol. 2020 Jun;95(6):594-603.
22. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy
in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226-33.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
124